GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivani Medical Inc (NAS:VANI) » Definitions » Asset Turnover

Vivani Medical (Vivani Medical) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Vivani Medical Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Vivani Medical's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Vivani Medical's Total Assets for the quarter that ended in Mar. 2024 was $49.79 Mil. Therefore, Vivani Medical's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Vivani Medical's annualized ROE % for the quarter that ended in Mar. 2024 was -97.66%. It is also linked to ROA % through Du Pont Formula. Vivani Medical's annualized ROA % for the quarter that ended in Mar. 2024 was -48.51%.


Vivani Medical Asset Turnover Historical Data

The historical data trend for Vivani Medical's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivani Medical Asset Turnover Chart

Vivani Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - - -

Vivani Medical Quarterly Data
Dec20 Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vivani Medical's Asset Turnover

For the Biotechnology subindustry, Vivani Medical's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivani Medical's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivani Medical's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Vivani Medical's Asset Turnover falls into.



Vivani Medical Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Vivani Medical's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (51.13+45.797)/ 2 )
=0/48.4635
=0.00

Vivani Medical's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (45.797+53.788)/ 2 )
=0/49.7925
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Vivani Medical  (NAS:VANI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Vivani Medical's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-24.156/24.7355
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-24.156 / 0)*(0 / 49.7925)*(49.7925/ 24.7355)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*2.013
=ROA %*Equity Multiplier
=-48.51 %*2.013
=-97.66 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Vivani Medical's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-24.156/49.7925
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-24.156 / 0)*(0 / 49.7925)
=Net Margin %*Asset Turnover
= %*0
=-48.51 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Vivani Medical Asset Turnover Related Terms

Thank you for viewing the detailed overview of Vivani Medical's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivani Medical (Vivani Medical) Business Description

Traded in Other Exchanges
Address
5858 Horton Street, Suite 280, Emeryville, CA, USA, 94608
Vivani Medical Inc is a preclinical stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases.
Executives
Gregg Williams director, 10 percent owner PO BOX 200, WALLED LAKE MI 48390-0200
Brigid Makes officer: CFO 20245 SW 95TH AVENUE, TUALATIN OR 97062
Donald Dwyer officer: Chief Business Officer 54 CHERRY FARM LANE, WEST CHESTER PA 19382
Aaron Mendelsohn director 224 15TH STREET, SANTA MONICA CA 90402
Joachim Eberhard Bolck 10 percent owner 33 CLUB VIEW LANE, ROLLING HILLS ESTATES CA 90274
Lisa Ellen Porter officer: Chief Medical Officer 778 CORDILLERAS AVE, SAN CARLOS CA 94070
Truc Le officer: COO 1905 WEST RED FOX ROAD, SANTA ANA CA 92704
Adam Mendelsohn director, officer: CEO C/O 5858 HORTON ST. SUITE 280, EMERYVILLE CA 94608
Wilford Dean Baker director 200 FLYNN ROAD, CAMARILLO CA 93012-8790
Larson Alexandra L.p. director 3797 BURNING TREE DRIVE, BLOOMFIELD HILLS MI 48302
Scott Dunbar officer: Acting CEO 13170 TELFAIR AVENUE, SYLMAR CA 91342
Edward Jonathon Sedo officer: Controller 4485 FORESTGLEN CT, MOORPARK CA 93021
Jessy Dana Dorn officer: VP-Clin & Scientific Affairs 12744 SAN FERNANDO RD. SUITE 400, SYLMAR CA 91342
Matthew J Pfeffer director
Patrick Ryan officer: Chief Operating Officer C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342